Biomarin Pharmaceutical Inc (BMRN)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 0.47 | 0.49 | 0.44 | 0.46 | 0.48 | 0.51 | 0.52 | 0.55 | 0.54 | 0.57 | 0.58 | 0.59 | 0.61 | 0.64 | 0.79 | 0.75 | 0.75 | 0.70 | 0.54 | 0.54 |
| Receivables turnover | 4.28 | 3.51 | 3.71 | 3.83 | 3.74 | 3.95 | 3.58 | 3.55 | 4.46 | 4.76 | 4.08 | 4.35 | 4.89 | 4.88 | 4.46 | 4.58 | 4.07 | 4.43 | 4.76 | 4.47 |
| Payables turnover | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Working capital turnover | 1.08 | 1.17 | 1.17 | 1.29 | 1.33 | 1.26 | 0.93 | 0.95 | 0.95 | 0.92 | 0.93 | 0.98 | 1.06 | 1.02 | 0.99 | 0.98 | 0.99 | 0.97 | 0.99 | 1.37 |
Based on the provided data for Biomarin Pharmaceutical Inc, let's analyze the activity ratios:
1. Inventory Turnover:
- The inventory turnover ratio measures how efficiently the company manages its inventory. Biomarin's inventory turnover has been fluctuating over the periods, ranging from 0.48 to 0.79. A decreasing trend could indicate possible inventory management issues or slower sales turnover.
2. Receivables Turnover:
- The receivables turnover ratio reflects how quickly the company collects its accounts receivable. Biomarin's receivables turnover has also varied over time, ranging from 3.51 to 4.89. A declining trend in this ratio may suggest potential difficulties in collecting outstanding receivables.
3. Payables Turnover:
- Unfortunately, the data does not provide information on Biomarin's payables turnover. This ratio is essential for evaluating how effectively the company manages its accounts payable, but its absence limits our ability to assess the efficiency of payment to suppliers.
4. Working Capital Turnover:
- The working capital turnover ratio indicates how efficiently the company is using its working capital to generate sales. Biomarin's working capital turnover has fluctuated between 0.92 and 1.33. A higher turnover indicates better utilization of working capital to drive revenue, while a decreasing trend may suggest inefficiencies in utilizing the available working capital.
In conclusion, Biomarin Pharmaceutical Inc's activity ratios show variability over time, indicating fluctuating efficiency in managing inventory, collecting receivables, and utilizing working capital. Further analysis and comparison with industry benchmarks would provide a more comprehensive assessment of the company's operational performance.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 775.41 | 742.72 | 832.16 | 799.82 | 763.05 | 722.52 | 698.64 | 667.91 | 674.72 | 643.53 | 631.98 | 614.19 | 602.50 | 573.56 | 461.62 | 488.84 | 486.33 | 517.80 | 675.07 | 674.85 |
| Days of sales outstanding (DSO) | days | 85.19 | 103.89 | 98.42 | 95.20 | 97.47 | 92.40 | 101.95 | 102.79 | 81.76 | 76.60 | 89.45 | 83.89 | 74.58 | 74.80 | 81.89 | 79.64 | 89.78 | 82.46 | 76.73 | 81.61 |
| Number of days of payables | days | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
The analysis of Biomarin Pharmaceutical Inc's activity ratios reveals some interesting trends.
1. Days of Inventory on Hand (DOH): The DOH measures how many days a company's inventory is held before being sold. Biomarin's DOH has shown fluctuations over the years, ranging from a low of 461.62 days in June 2021 to a high of 832.16 days in June 2024. This indicates potential challenges in managing inventory levels efficiently.
2. Days of Sales Outstanding (DSO): DSO measures how long it takes for a company to collect payment after making a sale. Biomarin's DSO has also varied, with a low of 74.58 days in December 2021 to a high of 103.89 days in September 2024. Higher DSO values suggest that the company may be facing difficulties in collecting payment promptly from customers.
3. Number of Days of Payables: Unfortunately, the data provided does not include information on Biomarin's number of days of payables, which would have helped in evaluating the company's payment practices with suppliers.
In conclusion, Biomarin Pharmaceutical Inc's activity ratios indicate challenges in managing inventory levels efficiently and collecting payments from customers promptly. Further analysis incorporating payables data would provide a more comprehensive view of the company's working capital management practices.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | 2.71 | 2.61 | 2.43 | 2.30 | 2.23 | 2.12 | 2.05 | 1.99 | 1.92 | 1.90 | 1.81 | 1.80 | 1.76 | 1.79 | 1.84 | 1.78 | 1.77 | 1.80 | 1.79 | 1.76 |
| Total asset turnover | 0.40 | 0.40 | 0.36 | 0.36 | 0.35 | 0.33 | 0.33 | 0.33 | 0.32 | 0.32 | 0.31 | 0.31 | 0.30 | 0.31 | 0.32 | 0.31 | 0.31 | 0.30 | 0.34 | 0.38 |
Biomarin Pharmaceutical Inc's long-term activity ratios indicate how efficiently the company is utilizing its assets to generate sales.
1. Fixed Asset Turnover:
- Biomarin's fixed asset turnover has been gradually increasing from 1.76 in March 2020 to 2.71 in December 2024. This suggests that the company is generating more revenue from its fixed assets over time.
- The peak in September 2024 at 2.71 indicates that Biomarin has significantly improved its efficiency in utilizing its fixed assets to generate sales.
- The consistent increase in fixed asset turnover over the years reflects positively on Biomarin's operational efficiency and effective utilization of its long-term assets.
2. Total Asset Turnover:
- Biomarin's total asset turnover has shown some fluctuations but generally remained in the range of 0.30 to 0.40 from March 2020 to December 2024.
- The company experienced a slight increase in total asset turnover towards the end of the period, reaching 0.40 in September and December 2024. This indicates that Biomarin is improving its overall efficiency in generating sales relative to its total assets.
- Although there were fluctuations, the overall trend suggests that Biomarin has been effectively managing its assets to drive sales growth.
In conclusion, Biomarin Pharmaceutical Inc has demonstrated improved efficiency in utilizing both fixed and total assets to generate sales over the evaluated period. The increasing trend in fixed asset turnover and the higher total asset turnover ratios reflect positively on the company's operational performance and asset utilization.